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Abstract The A1 adenosine and M2 muscarinic receptors ex-
ert protective (including energy consumption limiting) effects
in the heart. We investigated the influence of adenosine deam-
inase (ADA) inhibition on a representative energy consump-
tion limiting function, the direct negative inotropic effect elic-
ited by the A1 adenosinergic and M2 muscarinergic systems,
in eu- and hyperthyroid atria. Furthermore, we com-
pared the change in the interstitial adenosine level
caused by ADA inhibition and nucleoside transport blockade,
two well-established processes to stimulate the cell surface A1
adenosine receptors, in both thyroid states. A classical isolated
organ technique was applied supplemented with the receptorial
responsiveness method (RRM), a concentration estimating
procedure. Via measuring the contractile force, the direct neg-
ative inotropic capacity of N6-cyclopentyladenosine, a selec-
tive A1 receptor agonist, and methacholine, a muscarinic re-
ceptor agonist, was determined on the left atria isolated
from 8-day solvent- and thyroxine-treated guinea pigs in
the presence and absence of 2′-deoxycoformycin, a se-
lective ADA inhibitor, and NBTI, a selective nucleoside
transporter inhibitor. We found that ADA inhibition (but
not nucleoside transport blockade) increased the signal
amplification of the A1 adenosinergic (but not M2
muscarinergic) system. This action of ADA inhibition
developed in both thyroid states, but it was greater in
hyperthyroidism. Nevertheless, ADA inhibition produced
a smaller rise in the interstitial adenosine concentration
than nucleoside transport blockade did in both thyroid
states. Our results indicate that ADA inhibition, besides
increasing the interstitial adenosine level, intensifies the atrial
A1 adenosinergic function in another (thyroid hormone-
sensitive) way, suggesting a new mechanism of action of
ADA inhibition.
Keywords Adenosine deaminase inhibition .
Thyroid hormones . Heart . Atrium . Guinea pig . RRM
Introduction
With the exception of the low-income countries, diseases af-
fecting the cardiovascular system, primarily ischemic heart
disease and stroke, represent the biggest challenge in terms
of life expectancy (WHO 2014). Therefore, a basic under-
standing of endogenous protective mechanisms of the heart
against ischemia is a prerequisite for the development of new
rational therapeutic strategies (Perricone and Vander
Heide 2014; Kleinbongard and Heusch 2014). One pow-
erful endogenous protective mechanism in the living tissues
is adenosinergic signaling, a part of the ancient and ubiquitous
purinergic system (Verkhratsky and Burnstock 2014).
Effects of adenosine, a nucleoside of nucleic acid metabo-
lism, are mediated predominantly by activating G protein-
coupled adenosine receptors (Fredholm et al. 2001, 2011).
The main adenosine receptor type in the heart is the A1 aden-
osine receptor (A1 receptor), which is involved in extensive
protective and regenerative functions including negative
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tropic effects that limit energy consumption and thereby con-
tribute to the protection of the heart against ischemic–hypoxic
damages (Headrick et al. 2011, 2013). Pharmacological acti-
vation of the A1 adenosinergic system is a prospective, al-
though yet modestly utilized, possibility that may have pre-
ventive and therapeutic implications in numerous cardiovas-
cular maladies including ischemic heart disease and certain
types of arrhythmias (Szentmiklosi et al. 2011, 2015);
furthermore, it may come into play in avoiding hypoxic
injury during heart transplantation (Lim et al. 2013; Burnstock
and Pelleg 2014).
The thyroid state influences several regulatory mechanisms
including functions of the A1 receptor (for a brief review, see
Gesztelyi et al. 2012). Among others, thyroid hormones (T3,
T4) markedly reduce the direct negative inotropic effect (de-
crease of the contractile force without prior positive inotropic
stimulation exerted by another agent) of A1 receptor agonists
(Szentmiklosi et al. 1992; Kaasik et al. 1994; Gesztelyi et al.
2003a). Hyperthyroidism is a pathological condition that, by
upregulating a wide range of metabolic processes, raises the
oxygen and nutrient consumption in the tissues and thus in-
creases the work of the heart (Cini et al. 2009; Nabbout and
Robbins 2010). As a consequence, excess thyroid hormones
increase the risk of congestive heart failure, ischemic heart
disease, and arrhythmias and thereby elevate cardiovascular
mortality (Franklyn and Boelaert 2012). In light of these facts,
suppression of the A1 adenosinergic system by thyroid hor-
monesmay raise concerns. Thus, it is of importance to find out
possibilities to enhance the depressed function of the A1
adenosinergic system in hyperthyroidism.
An opportunity to influence the interstitial adenosine
concentration is to blunt enzymes participating in the
elimination of adenosine. Adenosine deaminase (ADA),
by converting adenosine into inosine, plays an important, al-
though not pivotal, role in the nucleic acid metabolism of the
heart (Fredholm et al. 2001, 2011; Headrick et al. 2011).
Inhibition (or deficiency) of ADA increases both the intra-
and extra-cellular adenosine concentrations that enables the
surplus adenosine to exert its effects via both intra- and
extra-cellular binding sites (Sandhu et al. 1993; Zhu et al.
1994; Hudspeth et al. 1994; Manthei et al. 1998; Peart et al.
2001, 2003; Willems et al. 2006; Abd-Elfattah et al. 2012).
Consistently, the inhibition of ADA augments actions of ex-
ogenous adenosine as well (Szentmiklosi et al. 1982;
Gesztelyi et al. 2003b).
In a previous study, we found that inhibition of ADA in-
creases the signal amplification of the A1 adenosinergic sys-
tem regarding its direct negative inotropic function in the hy-
perthyroid guinea pig atrium (Kemeny-Beke et al. 2007). As
ADA inhibition elevates the adenosine levels and thus aug-
ments all A1 receptor-mediated processes, it is not easy to
identify this particular (efficiency-enhancing) action of ADA
inhibition. Thus, the major goal of the present study was to
develop an experimental setup suitable to gain further insight
into the functional consequences of ADA inhibition as regards
the A1 receptor-mediated direct negative inotropy under both
eu- and hyperthyroid conditions.
Another way to manipulate the interstitial adenosine level is
inhibition of the adenosine flux across the cell membrane. In the
metabolically intact myocardium, adenosinemainly forms in the
interstitium and is eliminated in the cell interior; therefore, net
adenosine transport is directed into the cardiomyocytes
(Deussen et al. 1999; Deussen 2000a, 2000b). In the heart, the
transmembrane adenosine flux passes almost exclusively
through ENT1, a nucleoside transporter type that is equilibrative
and sensitive to inhibition by NBTI (Thorn and Jarvis 1996).
Accordingly, in our previous studies, NBTIwas found to elevate
the interstitial adenosine level in the guinea pig atrium (Karsai
et al. 2006; Kiss et al. 2013), an action which was more pro-
nounced in hyperthyroidism (Karsai et al. 2007; Pak et al. 2014).
As the ligand binding site of adenosine receptors is acces-
sible from the interstitium, it is especially important to gather
information about changes of the interstitial adenosine con-
centration. However, in the functioning heart, these data can-
not be assessed with sufficient accuracy (at least for our pur-
poses) by the commonly used methods because of the rapid
turnover and poor access of adenosine in the living tissues
(Karsai et al. 2006; Ramakers et al. 2008). Under well-
defined circumstances, the receptorial responsiveness method
(RRM), a method that has been recently developed but is
rooted in the classical pharmacology (Gesztelyi et al. 2004),
may address this problem. RRM is based on a simplified
mathematical modelling of the interaction between two ago-
nists that consume the response capacity of the same (or at
least greatly overlapping) signal transduction (Grenczer et al.
2010a, 2010b). This way, RRM enables the quantification of
an acute increase in the concentration of an agonist via gener-
ating concentration–effect (E/c) curves with the same or an-
other agonist (the latter of which is more stable or preferred for
any other reasons) in the given tissue. As a limitation, if the
two agonists are different, the surplus concentration in ques-
tion can be quantified only with a surrogate parameter, i.e., the
equieffective concentration of the other agonist. However, a
unique feature of RRM is that, owing to its functional assay
nature, it provides information about the agonist concentration
in the vicinity of the specific receptors, a tissue compartment
otherwise difficult to access in a working organ (Gesztelyi
et al. 2004; Grenczer et al. 2010a, 2010b). Although RRM,
in principle, can be applied for each receptor, the A1 receptor
is especially suitable for this purpose due to its slow desensi-
tization (Mundell and Kelly 2011) relative to the duration of
the measurement. Thus, another goal of the present study was
to assess the alteration in the interstitial adenosine level caused
by ADA inhibition by means of RRM and then to compare it
with the change produced by nucleoside transport blockade
under both eu- and hyperthyroid conditions.
854 Naunyn-Schmiedeberg's Arch Pharmacol (2015) 388:853–868
Methods
Materials
The following chemicals were used: L-thyroxine sodium
salt pentahydrate (T4), adenosine (non-selective adeno-
sine receptor full agonist), acetyl-β-methylcholine chloride
(methacholine:MC; non-selectivemuscarinic receptor full ag-
onist with high affinity for the M2 muscarinic receptor
(M2 receptor)), N
6-cyclopentyladenosine (CPA; selective
A1 adenosine receptor full agonist), 8-cyclopentyl-1,3-
dipropylxanthine (CPX; selective, competitive A1 adenosine
receptor antagonist), and S-(2-hydroxy-5-nitrobenzyl)-6-
thioinosine (NBTI; selective inhibitor of nucleoside transport-
er type ENT1) from Sigma (St. Louis, MO, USA) and
pentostatin (2′-deoxycoformycin: DCF; selective inhibitor of
adenosine deaminase) in Nipent™, which was the generous
gift of Wyeth Pharmaceuticals (Collegeville, PA, USA).
Experiments were conducted in modified Krebs–Henseleit
buffer (Krebs solution) that contained 118 mMNaCl, 4.7 mM
KCl, 2.5 mM CaCl2, 1 mM NaH2PO4, 1.2 mM MgCl2,
24.9 mM NaHCO3, 11.5 mM glucose and 0.1 mM ascorbic
acid (dissolved in redistilled water). T4 was dissolved in phys-
iological salt solution containing 0.01 % NaOH. Adenosine
and MC were dissolved at 36 °C in Krebs solution. CPAwas
dissolved in ethanol/water (1:4) solution (v/v). CPX and NBTI
were dissolved in dimethyl-sulfoxide (DMSO). DCF was dis-
solved in redistilled water (according to the manufacturer’s
instructions). Stock solutions were diluted with Krebs solution
(when appropriate). The concentration of ethanol and DMSO
did not exceed 0.023 % (v/v) and 0.1 % (v/v), respectively, in
the organ baths at any time.
Animals and preparations
All animal use protocols were approved by the Committee of
Animal Research, University of Debrecen, Hungary (3/2012/
DE MÁB). Male Hartley guinea pigs weighting 600–800 g
were used. A group of animals received 330 μg/kg T4 daily
(ip.) for 8 days (in vivo T4 treatment), while the vehicle of T4
was administered daily (ip.) for 8 days to the other group
(in vivo solvent treatment). On the ninth day, the animals were
guillotined; left atria were quickly removed andmounted at 10
mN resting tension in 10-ml vertical organ chambers
(Experimetria TSZ-04) containing Krebs solution gassed with
95 % O2 and 5 % CO2 (36 °C; pH 7.4). Atria were paced by
platinum electrodes (3 Hz, 1 ms, twice the threshold voltage)
by means of a programmable stimulator (Experimetria ST-02)
and power amplifier (Experimetria PST-02). The contractile
force was characterized by the amplitude of the isometric
twitches, which were detected by a transducer (Experimetria
SD-01) and strain gauge (Experimetria SG-01D), and record-
ed by a polygraph (Medicor R-61 6CH Recorder).
Experimental groups and protocols
First, all atria were allowed to equilibrate in Krebs solution for
40 min. Then, a cumulative concentration–effect (E/c) curve
was constructed with adenosine. After a washout period
(Krebs solution for 15 min), atria were randomized into
groups for the subsequent in vitro treatment. In the group
names, the applied in vivo and in vitro treatments (S—sol-
vent-treated, T—T4-treated, Co—control) and abbreviations
of the chemicals used were indicated: S Co (n=16), T Co
(n=19), S CPX (n=12), T CPX (n=9), S DMSO (n=6), T
DMSO (n=7), S NBTI (n=6), T NBTI (n=7), S DCF (n=10),
T DCF (n=18), S DCF CPX (n=8), T DCF CPX (n=9), S Co
(CPA) (n=7), T Co (CPA) (n=9), S DCF (CPA) (n=7), and T
DCF (CPA) (n=10).
The in vitro treatment included 20 min of incubation in the
presence of Krebs solution alone (S Co, T Co, S Co (CPA), T
Co (CPA)) or 10 μM CPX (S CPX, T CPX) or 0.1 % (v/v)
DMSO alone (S DMSO, T DMSO) or 10 μMNBTI (S NBTI,
T NBTI) or 10 μM DCF (S DCF, T DCF, S DCF (CPA), T
DCF (CPA)) or 10 μM DCF with 10 μM CPX (S DCF CPX,
T DCF CPX). Finally, a cumulative E/c curve was generated
with MC (S Co, T Co, S CPX, T CPX, S DMSO, T DMSO, S
NBTI, T NBTI, S DCF, T DCF, S DCF CPX, T DCF CPX) or
CPA (S Co (CPA), T Co (CPA), S DCF (CPA), T DCF (CPA))
(Fig. 1).
Rationale for the experimental design
In the present study, the direct negative inotropic func-
tion was assessed because it proved to be a strong, well-
measurable, and well-reproducible effect. Measurement was
carried out on isolated and paced left atria, a greatly
simplified model, in which the negative tropic effects
of different agonists could manifest only in a decrease
of the contractile force. This condition was important
for the acquisition of accurate data because the direct
component of negative inotropy is very sensitive to any
change in the frequency of contraction (Endoh 1999).
The reliability of the raw data was essential as oppor-
tunities inherent in RRM could be only exploited using
accurate input data.
Protocols of the present study consist of the construction of
two E/c curves and an in vitro treatment between them. For the
first E/c curve, adenosine was used to assess the responsive-
ness of the naïve (in vitro untreated) atrial A1 receptors.
Adenosine is especially suitable for this purpose because of
its rapid elimination without yielding confounding byproducts
(Wilbur andMarchlinski 1997). For the second E/c curve,MC
or CPA (two relatively stable agonists for the M2 or A1 recep-
tor, respectively) was administered in order to gather informa-
tion about the effect of the different in vitro treatments on the
M2 and A1 receptor responses. In the atrium, signaling
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pathways of these two receptors are almost the same
concerning the direct negative inotropic effect (Belardinelli
et al. 1995; Harvey and Belevych 2003).
According to the major goal of this study, the ADA
inhibitor DCF was administered during the in vitro
treatment to investigate the effects of ADA inhibition
on the atrial A1 adenosinergic system (which has a sig-
nificant overlap with the M2 muscarinergic machinery).
The A1 receptor antagonist CPX was added solely (to
check its effect alone) and together with DCF (to explore the
contribution of A1 receptors, activated by endogenous
adenosine evading the deamination by ADA, to the ef-
fect of DCF on the MC E/c curve). Blockade of the
inward adenosine transport elicited by NBTI was ap-
plied to generate data about the increase in concentra-
tion of interstitial adenosine in this particular experi-
mental setup (using MC) and thereby to enable the
comparison between ADA inhibition (by DCF) and nucleo-
side transport blockade (by NBTI) regarding their effect on the
interstitial adenosine level. DMSO treatment served as control
for the NBTI treatment (Fig. 1).
Characterization of E/c curves
The effect (defined as a percentage decrease in the initial con-
tractile force) obtained from the experiments was plotted
against the concentration of agonists administered. Both indi-
vidual and averaged E/c curves were fitted to the Hill equation
(Hill 1910):
E ¼ Emax ⋅ c
n
cn þ EC50n ð1Þ
where c is the concentration of the agonist administered, E is
the effect, Emax is the maximal effect, EC50 is the agonist
concentration producing a half-maximal effect, and n is the
Hill coefficient.
Hill parameters (Emax, EC50, n) of the individual E/c
curves were used for statistical analysis. Hill parame-
ters of some averaged E/c curves were applied for the
mathematical correction of some other E/c curves (see
below).
Comparison of E/c curves
The E/c curves were compared with each other in two man-
ners: by means of their effect values at each concentration and
per their Hill parameters. Three kinds of comparison were
made: (1) Within the same in vivo treated atria, the adenosine
E/c curves of different groups were compared with one anoth-
er. Similarly, the MC E/c curves of the control-type groups
(Co, CPX, DMSO) were also compared with one another
(within the same in vivo treatment); (2) The groups receiving
DCF and NBTI treatment were compared to their (same
in vivo treated) control counterparts; (3) The pooled adenosine
E/c curves of all T4-treated atria. Furthermore, the MC and
CPA E/c curves of some T4-treated control groups (T Co, T
DMSO, T Co (CPA)) were compared to their solvent-treated
counterparts.
Quantification of the E/c curve change caused by NBTI
and DCF
The surplus interstitial adenosine, accumulated over the basal
level in response to the inhibition of nucleoside transport or
ADA, modified (Bbiased^) the shape of the E/c curves con-
structed in the presence of NBTI or DCF. As DCF was found
previously to influence the signaling efficiency of atrial A1
adenosinergic system (Kemeny-Beke et al. 2007), the modi-
fied E/c curves generated with the A1 receptor agonist CPA
were excluded from the quantification (i.e., CPA E/c curves of
groups S Co (CPA), T Co (CPA), S DCF (CPA), and T DCF
(CPA)). The transformation of E/c curves constructed with
MC was quantified with the use of RRM (Gesztelyi et al.
Fig. 1 Conspectus of protocols and groups. The pivot of all protocols
was the construction of two E/c curves with an in vitro treatment inserted
into them. The inner and outer annuli of the pie chart represent the E/c
curves (showing the agonist used), and the medium annulus symbolizes
the in vitro treatment (indicating the applied chemicals in italic). Sectors
of the pie chart denote the particular protocols that progressed from the
inside out. The names of the experimental groups, which underwent the
protocols, are listed outside of the sectors. Two groups belong to one
protocol (one sector): one group including solvent-treated atria and
another one involving T4-treated atria. Ado adenosine, CPA N
6-
cyclopentyladenosine, MC methacholine, S solvent treatment, T T4
(thyroxine) treatment, Co control, Krebs Krebs solution, CPX 8-
cyclopentyl-1,3-dipropylxanthine, DMSO dimethyl-sulfoxide, NBTI
nitrobenzylthioinosine, DCF 2′-deoxycoformycin
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2004; Grenczer et al. 2010a) by fitting the averaged data of the
modified E/c curves to the following equation:
E0 ¼ 100 −
100 ⋅ 100 −Emax ⋅
cx þ cð Þn
cx þ cð Þn þ EC50n
 




where E′ is the averaged effect value of the modified MC E/c
curve of the group S NBTI, T NBTI, S DCF, or T DCF, Emax,
EC50, n is the Hill parameters of the corresponding control-
type averagedMCE/c curve of the group S DMSO, T DMSO,
S Co, or T Co, respectively, c is the concentration of MC
administered for the E/c curve, and cx is the MC concentration
that is equieffective with the surplus interstitial adenosine ac-
cumulated by NBTI or DCF.
Correction of effect values for the change produced
by NBTI and DCF
The correction procedure was performed as described previ-
ously (Kiss et al. 2013). First, an effect belonging to cx was
calculated by means of the Hill equation:
Ex ¼ Emax ⋅ cx
n
cxn þ EC50n ð3Þ
where Ex is the effect evoked solely by the surplus
interstitial adenosine produced by NBTI or DCF, cx is
the MC concentration conveyed by Eq. 2 (belonging to
the averaged MC E/c curve of the group S NBTI, T
NBTI, S DCF, or T DCF), Emax, EC50, n is the Hill parame-
ters of the corresponding control-type E/c curve (i.e., the av-
eraged MC E/c curve of the group S DMSO, T DMSO, S Co,
or T Co, respectively).
Then, from effect values of a modified E/c curve (E′) and
the corresponding Ex, corrected effect values were computed
with the use of the following equation:
E ¼ 100 − 100 −E
0ð Þ ⋅ 100 − Exð Þ
100
ð4Þ
where E is the corrected effect, E′ is the modified effect, and
Ex is the effect of the surplus interstitial adenosine produced by
NBTI or DCF (belonging to the averagedMC E/c curve of the
group S NBTI, T NBTI, S DCF, or T DCF).
In order to correct the effect values of MC E/c curves of
groups S NBTI, T NBTI, S DCF, and T DCF, the averaged
modified effects of these E/c curves (as E′) and the corre-
sponding Ex values were substituted into Eq. 4. For the
correction of CPA E/c curves of groups S DCF (CPA) and T
DCF (CPA), the averaged modified effects of these E/c curves
were substituted into Eq. 4 along with Ex values belonging to
the averaged MC E/c curves of groups S DCF and T DCF,
respectively. The reason of doing this was that the amount and
effect of the surplus interstitial adenosine produced by DCF
did not depend on the nature of the agonist used for a subse-
quent E/c curve. All corrected effects were plotted versus the
MC and CPA concentrations administered for the given E/c
curve.
Data analysis and presentation
Each atrium was required to meet three criteria in order
to qualify for inclusion in the statistical analysis: (1) the
initial contractile force had to reach 1 mN before the
first E/c curve; (2) the mechanical activity of the paced
atrium had to be regular; and (3) the response to 10 or
100 μM adenosine of the solvent- or T4-treated atrium,
respectively, was required to be within a mean±2 SD
range. The mean and SD were computed using atria
meeting the first two criteria (separately for the solvent-
and T4-treated population). All experimental outcomes
conforming to these three criteria were subjected to statistical
workup.
According to the recommendation of Motulsky and
Christopoulos (2004), concentrations in the equations used
for curve fitting (c, EC50, and cx) were expressed as common
logarithms.
Hill parameters of the pooled adenosine E/c curves (sol-
vent-treated atria vs. T4-treated ones) and raw E/c data of
selected E/c curve pairs were compared with unpaired
Student t test or t test with Welch’s correction (if equal vari-
ance test was not passed) or Mann–Whitney U-test (if either
equal variance test or normality test was not passed). Hill
parameters of adenosine E/c curves of the different groups
were compared (separately for the solvent and T4 treatment)
by one-way ANOVA (using Geisser–Greenhouse correction)
with Tukey post-testing or byKruskal–Wallis test with Dunn’s
post-testing (if the normality test was not passed). Hill param-
eters of the MC and CPA E/c curves were compared using
two-way ANOVA with Sidak post-testing (as all data sets
passed the normality test). Statistical significance for the dif-
ference of means (or medians) was assigned into one of four
categories: p>0.05 (not significant), p<0.05 (one mark),
p<0.01 (two marks), or p<0.001 (three marks).
Data presented in this paper are expressed as mean±
SEM or value with lower and upper 95 % confidence
interval limits. Curve fitting and statistical analysis were
performed with the use of GraphPad Prism 6.05, while
other calculations were made by means of Microsoft
Office Excel 2013.
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Results
Thyroid state
By the ninth day, body weight of the solvent- and T4-treated
guinea pigs were altered from 712±11 to 723±11 g and from
719±12 to 538±11 g (p<0.001), respectively. The ratio of left
atrial weight to body weight in the solvent- and T4-treated
group was 0.089±0.009 and 0.132±0.009 mg/g (p<0.001),
respectively.
Initial contractile forces
The initial contractile forces, measured prior to the in vitro
treatment (before the first E/c curve), did not differ significant-
ly either between the pooled solvent- and T4-treated atria
(9.3±0.35 and 8.67±0.4 mN, respectively) or among the dif-
ferent groups (Fig. 2).
During the in vitro treatment, CPX non-significantly mod-
erated the small decay in the contractile force over time as
compared to the corresponding controls. In contrast, both
NBTI and DCF decreased the atrial contractile forces, al-
though this effect was significant only in the case of NBTI
(p<0.05). The co-treatment with DCF and CPX produced an
outcome similar to the corresponding controls; thus, DCF and
CPX appeared to mutually cancel out each other’s effects.
Contractile forces of the different T4-treated groups did not differ
significantly from their solvent-treated counterparts (Fig. 2).
Adenosine E/c curves
Response to adenosine Adenosine concentration dependent-
ly reduced the contractile force of atria (Fig. 3). As no
previous intervention evoking positive inotropic effect
was done, the response to adenosine was considered
direct negative inotropic effect that is typical for the
atrial (but not ventricular) myocardium (Belardinelli
et al. 1995; Kurachi 1995).Comparison before the
in vitro treatment Responses to the different adenosine
concentrations (data not shown) as well as Hill parameters of
the adenosine E/c curves (Table 1) did not differ significantly
when compared among the same in vivo-treated groups with
one another. Thus, the solvent- and T4-treated atria formed
two homogenous populations regarding the response to
adenosine.
Effect of T4 on the response to adenosine The responses to
adenosine at the different concentrations (except the starting
0.1 μM) showed a significant decrease when comparing the
pooled T4-treated atria to the pooled solvent-treated ones
(Fig. 3). Consistently, the T4 treatment diminished Emax,
Fig. 2 The contractile force of guinea pig left atria in the different groups
before and after the in vitro treatment. The open columns show the
contractile forces of atria measured before the in vitro treatment
(mean+SEM). The shorter filled columns in front of the open ones
denote the contractile forces determined at the end of the in vitro
treatment (mean − SEM). The homogeneous light grey filling means an
in vitro treatment containing neither NBTI nor DCF, while light grey
filling with darker or less dark pattern shows an in vitro treatment
containing NBTI or DCF, respectively. Group names are indicated
below the columns. Comparing the contractile forces of the different
in vitro-treated groups (filled columns), a significant difference was
found only in the case of NBTI: S Co vs. S NBTI, S CPX vs. S NBTI,
T Co vs. T NBTI, and T CPX vs. T NBTI (asterisk)
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Fig. 3 The direct negative inotropic effect of adenosine (Ado) in solvent-
treated (S; open symbols) or T4-treated (T; filled symbols) guinea pig left
atria (before any in vitro treatment). The x-axis shows the common
logarithm of the molar concentration of adenosine, and the y-axis
denotes the effect as a percentage decrease of the initial contractile
force. The symbols indicate the responses to adenosine that were
averaged after pooling the same in vivo-treated groups (± SEM). The
curves illustrate the fitted Hill equation (Eq. 1). The responses to
adenosine differed significantly between the pooled groups (asterisk)
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increased logEC50, and decreased n of these pooled adenosine
E/c curves in a statistically significant manner (Table 1).
MC E/c curves
Response to MC MC also decreased the contractile force of
atria in a concentration-dependent manner (direct negative
inotropic effect) (Figs. 4, 5, 6, and 7).
Effect of CPX and DMSO on the response to MC The
control-type groups (Co, CPX, DMSO) receiving the same
in vivo treatment did not differ significantly from one another
when either the responses to the different MC concentrations
(Fig. 4) or the Hill parameters of the MC E/c curves (data not
shown) were compared. This observation indicates that
DMSO, vehicle of CPX and NBTI, and CPX did not influence
significantly the response to MC. Nevertheless, a minor differ-
ence can be shown between groups SCo vs. S DMSO and TCo
vs. T DMSO (Fig. 4b). Based on prior experiences of our team
with DMSO, this cannot be ascribed to the effect of DMSO but,
rather, to the fact that investigations usingNBTI (including their
controls) were performed after experiments using CPX and
DCF (and their controls). Seasonal differences can affect the
atrial inotropic response (Kemeny-Beke et al. 2007).
Effect of T4 on the response to MC Based on the compari-
son of groups T Co and T DMSO to their solvent-treated
counterparts (S Co and S DMSO), the T4 treatment moderate-
ly suppressed the response to MC that was only significant at
higher MC concentrations (Fig. 4). In line with this, the T4
treatment caused a moderate diminution in Emax (significant)
and n (on the border of statistical significance), while the
increase of logEC50 did not reach the significance threshold
(Table 2).
Modification of the response to MC by NBTI In both the
solvent- and T4-treated groups, NBTI significantly reduced
the response to MC according to the conventionally plotted
(and thereby modified) E/c curves (Fig. 5). This manifested in
a significant decrease of Emax and in a minor increase of
logEC50 with a practically unchanged n (Table 2). The effect
of NBTI was more intense in the group T NBTI than in the
group S NBTI (Fig. 5; Table 2).
Effect of NBTI on the interstitial adenosine level Based on
the depression of the conventionally plotted MC E/c curves
generated in the presence of NBTI (Fig. 5), the surplus inter-
stitial adenosine was found to be equieffective with 101.2 and
151.1 nMMC in the solvent- and T4-treated atria, respectively
(Table 3). It means that nucleoside transport blockade pro-
duces a greater interstitial adenosine accumulation in the T4-
treated atria than in the solvent-treated ones, consistent with
our earlier studies in which CPA served as an agonist for the E/
c curves (Karsai et al. 2007; Pak et al. 2014).
Modification of the response to MC by DCF DCF de-
creased the response toMC in both the solvent- and T4-treated
atria according to the conventionally plotted (modified) E/c
curves. This modification was rather symbolic under euthy-
roid conditions (Fig. 6a), while it was well marked in hyper-
thyroidism (Fig. 6b). In turn, CPX abolished this effect of
DCF on the MC E/c curves in both thyroid states (Fig. 7).
These observations indicate that DCF exerted its effect on
the response to MC the same way as NBTI did, i.e., via ele-
vating the interstitial adenosine level. It should be noted that
the effect of DCF on the response to MC was statistically
significant only in the T4-treated atria (except for the response
at 10 nM MC in the group S DCF, but it was considered
irrelevant) (Fig. 6). Consistently, the decrease of Emax was
only significant in the group T DCF (Table 2).
Effect of DCF on the interstitial adenosine level Fitting
Eq. 2 to MC E/c data of groups S DCF and T DCF (Fig. 6),
the surplus interstitial adenosine proved equieffective with
28.05 and 44.36 nM MC in the solvent- and T4-treated atria,
respectively (Table 3). This outcome is similar to that seen in
response to NBTI (Table 3), namely, DCF appears to produce
a greater interstitial adenosine accumulation in the T4-treated
Table 1 Hill parameters of the first E/c curve generated with adenosine
(before the in vitro treatment indicated in the group names)
Ado curves Emax logEC50 n (mean±SEM)
S-pooled 88.27±0.65 −5±0.03 0.9±0.03
T-pooled 84.53±0.84** −3.96±0.03*** 0.66±0.01***
S Co 89.76±1.24 −4.99±0.06 0.8±0.05
S CPX 87.42±1.7 −4.94±0.1 0.93±0.07
S DMSO 87.59±1.58 −5.03±0.1 0.94±0.08
S NBTI 89.59±3.05 −4.9±0.08 0.97±0.15
S DCF 88.89±0.62 −5.12±0.02 0.91±0.03
S DCF CPX 88.04±1.03 −5±0.06 0.88±0.04
S Co (CPA) 87.78±1.41 −5.05±0.04 0.94±0.04
S DCF (CPA) 90.79±0.91 −5±0.08 0.94±0.06
T Co 85.81±1.91 −3.9±0.06 0.63±0.02
T CPX 82.92±1.96 −4±0.1 0.72±0.05
T DMSO 81.89±2.4 −3.97±0.1 0.72±0.04
T NBTI 82.35±2.89 −4.05±0.09 0.67±0.03
T DCF 86.05±2.29 −3.88±0.06 0.62±0.03
T DCF CPX 85.73±2.82 −3.92±0.06 0.66±0.04
T Co (CPA) 83.92±2.59 −4.08±0.08 0.75±0.05
T DCF (CPA) 82.06±2.67 −4.06±0.11 0.74±0.04
Emax, logEC50 and n (mean±SEM) are best-fit values of the Hill equation
(Eq. 1) fitted to the individual adenosine E/c curves. Comparison was
made between the pooled solvent (S)- and pooled T4 (T)-treated groups,
furthermore within the same in vivo treated groups. Significant differ-
ences were found between the pooled groups (asterisk)
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atria than in the solvent-treated ones (Table 3). However,
due to reasons specified in BDiscussion^, this latter find-
ing should be treated with caution. Nevertheless, DCF
increased the interstitial adenosine level to a smaller
extent than NBTI did in both the solvent- and T4-treated
groups (Table 3).
CPA E/c curves
Response to CPA CPA also reduced the atrial contractile
force in a concentration-dependent manner (direct negative
inotropic effect) (Fig. 8).
Effect of T4 on the response to CPA Comparing groups T
Co (CPA) and S Co (CPA), the T4 treatment considerably
decreased the response to CPA that was significant from me-
dium to high concentrations (Fig. 8). In agreement with this, T4
treatment significantly reduced both Emax and n and increased
logEC50 (Table 2). Thus, T4 induced a greater depression of the
E/c curve for CPA than for MC (Figs. 4 and 8; Table 2).
Modification of the response to CPA by DCF In contrast to
that seen with MC (Fig. 6), DCF augmented the response to
CPA in both the solvent- and T4-treated atria, according to the
conventionally plotted (modified)E/c curves.While this effect











































































BFig. 4 a, b The direct negative
inotropic effect of MC in the
presence of CPX or DMSO
(alone) or in the absence of both
of them (Co) in solvent-treated
(open/thin symbols) or T4-treated
(filled/thick symbols) guinea pig
left atria. The x-axis shows the
common logarithm of the molar
concentration of MC, while the
y-axis indicates the effect as a
percentage decrease of the initial
contractile force of atria. The
symbols represent the responses
toMC averaged within the groups
(± SEM), and the curves illustrate
the fitted Hill equation (Eq. 1).
The responses to MC differed
significantly between groups S
Co vs. T Co and S DMSO vs. T
DMSO (asterisk)







































































BFig. 5 The direct negative
inotropic effect of MC in the
presence of DMSO (alone) or
NBTI in solvent-treated (open
symbols in a) or T4-treated (filled
symbols in b) guinea pig left atria.
The x-axis shows the common
logarithm of the molar
concentration of MC, and the y-
axis indicates the effect as a
percentage decrease of the initial
contractile force of atria. The
symbols denote the responses to
MC averaged within the groups
(± SEM), and the dotted curves
illustrate the fitted RRM model
(Eq. 2). The responses to MC
differed significantly between
groups S DMSO vs. S NBTI and
T DMSO vs. T NBTI (asterisk)
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of DCF was minor in the solvent-treated atria, it was signifi-
cant in the T4-treated ones in the lower and medium concen-
tration ranges (Fig. 8). In agreement with this, DCF signifi-
cantly decreased logEC50 of E/c curves of T4-treated but not
solvent-treated atria (Table 2). This outcome is consistent with
our previous finding that inhibition of ADA enhances the
efficiency of the direct negative inotropic function mediated
by the A1 receptor in the hyperthyroid guinea pig atrium
(Kemeny-Beke et al. 2007).
Corrected MC and CPA E/c curves
The corrected E/c curves have two points of interest, the
starting and final ones. The starting point shows Ex, the effect





































































BFig. 6 The direct negative
inotropic effect of MC in the
absence or presence of DCF in
solvent-treated (open symbols in
a) or T4-treated (filled symbols in
b) guinea pig left atria. The x-axis
denotes the common logarithm of
the molar concentration of MC,
and the y-axis indicates the effect
as a percentage decrease of the
initial contractile force of atria.
The symbols show the responses
toMC averaged within the groups
(± SEM), and the dotted curves
illustrate the fitted RRM model
(Eq. 2). The responses to MC
differed significantly between
groups S Co vs. S DCF and T Co
vs. T DCF (asterisk)

































Fig. 7 The direct negative inotropic effect of MC in the absence or
presence of DCF added together with CPX in solvent-treated
(open symbols) or T4-treated (filled symbols) guinea pig left
atria. The x-axis denotes the common logarithm of the molar
concentration of MC, and the y-axis indicates the effect as a
percentage decrease of the initial contractile force of atria. The symbols
show the responses to MC averaged within the groups (± SEM), and the
curves illustrate the fitted Hill equation (Eq. 1)
Table 2 The Hill parameters exhibiting statistically significant change
in response to the different in vivo (asterisk) or in vitro (not-equal-to
symbol) treatments
Emax logEC50 n (mean±SEM)
MC curves
S Co 95.5±0.41 1.18±0.03
S DMSO 97.52±0.81
S NBTI 90.23±0.75≠≠





S Co (CPA) 90.9±1.59 −7.86±0.08 1.06±0.05
T Co (CPA) 84.04±1.01** −7.5±0.06** 0.7±0.04***
T DCF (CPA) −7.77±0.08≠
Emax, logEC50 and n (mean±SEM) are best-fit values of the Hill equation
(Eq. 1) fitted to the individual E/c curves generated with MC or CPA.
Significant differences were found between groups S Co vs. T Co, S
DMSO vs. T DMSO, and S Co (CPA) vs. T Co (CPA) (asterisk), further-
more with S DMSO vs. S NBTI, T DMSO vs. T NBTI, T Co vs. T DCF,
and T Co (CPA) vs. T DCF (CPA) (not-equal-to symbol)
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belonging to cx, while the last point reflects the maxi-
mal response of the given system to the agonist in
question. As cx values have been addressed previously,
herein the emphasis is on the final point of the corrected E/c
curves, specifically on its position relative to the last point of
the corresponding control E/c curve (the latter considered to
be a priori correct).
NBTI with MC The corrected MC E/c curves (generated in
the presence of NBTI) ended somewhat below their control
curves (Fig. 9a, b). Thus, if we consider the observed small
difference between maximal values of the corrected and con-
trol E/c curves to be an error, it can be concluded that NBTI
does not affect the efficiency of the M2 muscarinergic signal-
ing, irrespective of the thyroid state (Fig. 9a, b).
DCF with MC The corrected MC E/c curves (constructed in
the presence of DCF) ran to the maximum of their
control curves (Fig. 9c, d). Conclusions to be drawn
from this outcome are the same as those with NBTI, i.e.,
DCF does not influence the signal amplification of the atrial
M2 muscarinergic mechanisms, regardless of the T4 treatment
(Fig. 9c, d).
DCF with CPA Effect values of the corrected CPA E/c
curves (generated in the presence of DCF) exceeded their
control effect values at each concentration, even at the highest
one (Fig. 9e, f). This finding indicates that DCF augments the
efficiency of the A1 adenosinergic system regarding its direct
negative inotropic function in the guinea pig atrium. This phe-
nomenon was visibly more pronounced in the T4-treated atria
(Fig. 9e, f), in agreement with our previous finding (Kemeny-
Beke et al. 2007). However, the present result denotes that
DCF can exert its efficiency-enhancing effect even in the eu-
thyroid state.
Discussion
The first finding of the present study is that, in the guinea pig
atrium, ADA inhibition (but not nucleoside transport
blockade) enhances the efficiency of the direct negative
inotropic function of the A1 adenosine (but not M2
muscarinic) receptor. This finding suggests that inhibi-
tion of ADA affects the atrial A1 adenosinergic system
in a part other than the joint signaling pathways of the
A1 and M2 receptors. Second, ADA inhibition enhances
the A1 adenosinergic direct negative inotropy even in
the euthyroid state, although to a less extent than in
hyperthyroidism. This outcome implies that ADA inhi-
bition can partially reset the A1 receptor-mediated direct
negative inotropy suppressed by thyroid hormones. Third,
ADA inhibition produces a smaller rise in the interstitial
Table 3 The cx values obtained with RRM characterizing the
concentration of the surplus interstitial adenosine produced by NBTI or
DCF in solvent (S)- or T4 (T)-treated guinea pig left atria
Logcx 95% CI cx (nmol/l)
From To
S DMSO −12.62 −18,000 17,975 0.00024
S NBTI −6.99 −7.1 −6.88 101.2
T DMSO −9.07 −17.62 −0.53 0.84
T NBTI −6.82 −6.93 −6.72 151.1
S Co −13.98 −91,603 91,576 0.00001
S DCF −7.55 −7.73 −7.37 28.05
T Co −53.25 Ambiguous 0
T DCF −7.35 −7.45 −7.26 44.36
The logcx is the best-fit value of Eq. 2 fitted to the averaged E/c curves
generated with MC in the presence of DMSO or NBTI or DCF or in the
absence of all of them (Co). Precision of the fit was characterized with the
95 % confidence interval (95 % CI) for the best-fit value. Fitting of the
control-type groups (S DMSO, T DMSO, S Co, T Co) to Eq. 2 served
only for verification; the expected value of cx was 0. In turn, fitting of the
groups S NBTI, T NBTI, S DCF, and T DCFwas expected to provide a cx
value (shown in italic) that indicates the MC concentration equieffective
with the surplus interstitial adenosine produced by NBTI or DCF
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Fig. 8 The direct negative inotropic effect of CPA in the absence or
presence of DCF in solvent-treated (open/thin symbols) or T4-treated
(filled/thick symbols) guinea pig left atria. The x-axis shows the
common logarithm of the molar concentration of CPA, while the y-axis
indicates the effect as a percentage decrease of the initial contractile
force of atria. The symbols denote the responses to CPA averaged
within the groups (± SEM), and the curves represent the fitted Hill
equation (Eq. 1). The responses to CPA differed significantly between
groups S Co (CPA) vs. T Co (CPA) (asterisk) and T Co (CPA) vs. T DCF
(CPA) (not-equal-to symbol)
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adenosine concentration than nucleoside transport blockade
does. Fourth, our results demonstrate that T4 treatment sup-
presses the direct negative inotropic function of the M2 receptor
in a guinea pig model as well. Nevertheless, this reduction in the
M2 muscarinergic function in response to thyroid hormones is
quite small relative to the decrease in the A1 adenosinergic one.




































































































































































































Fig. 9 a–f The corrected direct
negative inotropic effect values of
concentration–effect curves
generated in the presence of NBTI
or DCF, plotted versus the
concentration of the administered
MC or CPA, together with the
corresponding control
concentration–effect curves
(in their original form). The
correction was made for the direct
negative inotropic effect of the
surplus interstitial adenosine
produced by NBTI or DCF in a
manner that this effect value has
been incorporated into the effect
data depicted herein. The x-axis
indicates the agonist
concentration on a base-10
logarithmic scale, and the y-axis
shows the effect as a percentage
decrease in the initial contractile
force of atria. The symbols (open/
thin solvent treatment, filled/thick
T4 treatment) represent the
corrected effects computed from
the raw effects averaged within
the groups
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Previously we found that ADA inhibition elicited by DCF
potentiated the direct negative inotropic effect of CPA, a se-
lective A1 receptor agonist, in the hyperthyroid guinea pig
atrium (Kemeny-Beke et al. 2007). Since CPA is not a sub-
strate for ADA (Pavan and Ijzerman 1998), this counterintui-
tive result was attributed to the fact that ADA inhibition in-
creases the signal amplification of the atrial A1 receptor and/or
its downstream signaling pathways under hyperthyroid condi-
tions. We assumed that this efficiency-enhancing effect of
ADA inhibition may be associated with intracellular adeno-
sine accumulation rather than the interstitial one (the latter of
which is otherwise responsible for the stimulation of the cell
surface A1 receptors, a known trigger of several beneficial
effects of ADA inhibition; Zhu et al. 1994; Peart et al. 2001;
Willems et al. 2006; Szentmiklosi et al. 2011). This assump-
tion is supported by the fact that blockade of the physiologi-
cally inward nucleoside transport, which also increases the
interstitial adenosine concentration but decreases the intracel-
lular one (Deussen 2000a, 2000b), does not enhance the effi-
ciency of the atrial A1 adenosinergic system under either eu-
thyroid or hyperthyroid conditions (Karsai et al. 2006, 2007).
The major difficulty to investigate this phenomenon is the
fact that ADA inhibition, besides enhancing the efficiency of
A1 receptor function (an effect first described by Kemeny-
Beke et al. in 2007), elevates the tissue adenosine content that
leads to A1 receptor activation that also augments the A1
receptor-mediated functions (a well-known effect). In the ex-
perimental setup used for the above-mentioned study
(Kemeny-Beke et al. 2007), this problem occurred in a form
such that the decrease of the contractile force (evoked by the
surplus interstitial adenosine caused by ADA inhibition) inter-
fered with the efficiency-enhancing effect of ADA inhibition
on the A1 receptor-mediated direct negative inotropy. To clar-
ify this case, we provide a brief explanation. When DCF had
been administered, the interstitial adenosine level increased,
and the surplus adenosine exerted a direct negative inotropic
effect on the atria. So, this condition served as baseline for
further manipulations, i.e., administration of CPA to
generate an E/c curve. As the surplus interstitial adenosine
had already consumed a part of the response capacity of the
A1 adenosinergic system, a modified (smaller than expected)
response to CPA was detected (for more details about this
phenomenon, see Gesztelyi et al. 2004; Grenczer et al.
2010a). Thus, the two actions of ADA inhibition (mentioned
at the top of this paragraph) worked against each other in our
earlier experimental setup (Kemeny-Beke et al. 2007).
In the present study, we aimed to separate these two actions
of ADA inhibition in order to gain a deeper understanding of
the influence of ADA inhibition on the regulation of contrac-
tility of the atrium. To address this challenge, we repeated our
previous experiments with the replacement of CPAwithMC, a
muscarinic receptor agonist with high affinity for the M2
receptor.
In the heart, the A1 and M2 receptors are the predominant
receptor types for adenosine (Headrick et al. 2013; Ijzerman
et al. 2014) and acetylcholine (Harvey 2012; Birdsall et al.
2014), respectively. In the atrium, both A1 and M2 receptors
bind to Gi/0 proteins, and thereby both of them can open the
muscarinic-operated potassium channel and blunt the adenylyl
cyclase activity with the consequent inhibition of all cAMP-
dependent signaling pathways (Caulfield and Birdsall 1998;
Fredholm et al. 2001, 2011; Harvey and Belevych 2003;
Harvey 2012; Headrick et al. 2011, 2013). As a consequence,
both A1 and M2 receptors can mediate a direct negative inotro-
pic effect (Belardinelli et al. 1995; Kurachi 1995). Thus, al-
though via binding to different receptors, CPA andMC activate
greatly overlapping signal transduction pathways in the atrium.
The key concept of the experimental design used for the
present study is as follows: If the A1 receptor and ADA are
inhibited simultaneously, the direct negative inotropic effect
of the surplus interstitial adenosine produced by ADA inhibi-
tion can be prevented (with the consequent preservation of the
response capacity of the A1 adenosinergic system). However,
the major signaling pathways underlying the direct negative
inotropy remain accessible from theM2 receptor. In this setup,
if the molecular target, the change of which is responsible for
the enhanced efficiency of the direct negative inotropic func-
tion of the A1 receptor under ADA inhibition, is located in the
joint part of the postreceptorial signaling of A1 and M2 recep-
tors, an enhanced response to MC is expected relative to the
naïve state (lacking A1 receptor antagonist and ADA inhibi-
tor). If this is the case, we succeed in narrowing the circle of
possible mechanisms of action for the efficiency-enhancing
effect of ADA inhibition. If not, besides narrowing the circle
of possible action mechanisms (i.e., the molecular target in
question is out of the shared part of signaling of the A1 and
M2 receptors), we have the opportunity to quantify the con-
centration of the surplus interstitial adenosine produced by
ADA inhibition. This is because a prerequisite of the quanti-
fication is the fixedness of signal amplification properties of
the M2 muscarinergic system throughout the investigation.
Results of a preliminary study, carried out in our laboratory
using a simple protocol and small sample size, suggested that
ADA inhibition might enhance the response to MC (in addi-
tion to CPA) (Grenczer et al. 2007). During the present inves-
tigation, we have expanded our protocol with the use of CPX,
a selective A1 receptor antagonist, and applied a sufficiently
large sample size. Our current results show that, in the pres-
ence of CPX, ADA inhibition afforded by DCF was unable to
influence the response to MC (Fig. 7). Thus, we have every
reason to conclude that ADA inhibition does not affect the
shared part of postreceptorial signaling of A1 and M2 recep-
tors. Therefore, we could quantify the effect of ADA inhibi-
tion on the interstitial adenosine concentration and then com-
pare it with the similar action of nucleoside transport blockade
(by NBTI).
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The response to MC during inhibition of the nucleoside
transport or ADA (without A1 receptor blockade) showed a
decrease relative to the naïve state. This phenomenon was due
to the fact that the surplus interstitial adenosine, by activating
the A1 adenosinergic machinery, modified (Bbiased^) the ef-
fect mediated by the M2 receptor. Namely, because of the
overlapping signaling pathways, when a fraction of the re-
sponse capacity of the A1 adenosinergic system was depleted,
the responsiveness of the M2 muscarinergic system also de-
creased (Gesztelyi et al. 2004). The magnitude of the change
(Bbias^) of the E/c curve is characteristic of the magnitude of
the modifying effect (Grenczer et al. 2010a).
To estimate the surplus interstitial adenosine from the mod-
ification of MC E/c curves, RRM presented itself. The motif
of RRM is the interchangeability of agonists evoking the same
kind of effect, irrespective of what sort of receptor they bind to
(Gesztelyi et al. 2004; Grenczer et al. 2010a, 2010b). In the
present case, RRM has quantified the surplus interstitial adeno-
sine with a surrogate parameter, i.e., the equieffective MC
concentration (cx).
The cx values of the present study show that NBTI substan-
tially elevated the interstitial adenosine level, and this effect
was greater in the hyperthyroid guinea pig atrium than in the
euthyroid one (Table 3). This finding corroborates our previ-
ous results about the effect of NBTI, in which cx values were
obtained as equieffective CPA concentrations (Karsai et al.
2006, 2007; Kiss et al. 2013; Pak et al. 2014).
The cx values of the present study also indicate that DCF,
similarly to NBTI, increased the interstitial adenosine level in
both the eu- and hyperthyroid guinea pig atria. Expressing this
action in numbers, NBTI produced an about 3.5-fold greater cx
than DCF did, irrespectively of the thyroid state (Table 3).
This denotes that the nucleoside transport blockade has greater
influence on the interstitial adenosine level than ADA inhibi-
tion (under our ex vivo conditions ensuring a well-oxygenated
bathing medium). However, nucleoside transport inhibitors
increases the interstitial adenosine level only in the metaboli-
cally intact myocardium (Deussen et al. 1999; Deussen 2000a,
2000b). In hypoxia, nucleoside transport blockers can
decrease the interstitial adenosine level by inhibiting
the adenosine release from the cells (Görge et al.
1998; Schreieck and Richardt 1999). Thus, to elevate
the interstitial adenosine concentration, ADA inhibition
appears to be an intervention more reliable than nucle-
oside transport blockade. It should be noted that ADA
inhibitors have a wide range of actions throughout the
body that forms the basis for several side effects (Bazl
et al. 2012). However, these side effects are less prob-
lematic if ADA inhibitors are applied in an isolated organ
rather than the whole body, e.g., in a heart to be transplanted.
ADA inhibitors have been found to reduce hypoxic injury
during cardiac surgery (Zhu et al. 1994; Hudspeth et al.
1994; Abd-Elfattah et al. 2013).
Because of unaltered signal amplification properties of the
M2 muscarinergic system under ADA inhibition (Figs. 7 and
9c, d), cx values obtained from MC E/c curves could be used
to correct the conventionally plotted MC and CPA E/c curves
generated in the presence of NBTI and DCF (without CPX)
for the change produced by the surplus interstitial adenosine.
As the exact concentration of extra adenosine at the A1 recep-
tors remained unknown, the modified effect values were only
corrected, and then they were plotted against the concentration
of the agonist administered for the E/c curve. Therefore, the
two most useful points of the corrected E/c curves are those at
zero and at the highest concentration. The starting point shows
the effect evoked by the surplus interstitial adenosine alone (Ex),
while the final one represents the maximal response of the
given system to the given agonist (owing to the fact that
well-saturated E/c curves were corrected).
The most important feature of the corrected MC E/c curves
is that all of them end practically ibidem as their controls
(considered to be inherently correct). This behavior of the
curves confirms that the efficiency of the M2 muscarinergic
control on atrial contractility did not change in response to the
inhibition of either nucleoside transport or ADA (Fig. 9a–d).
In contrast, the corrected CPA E/c curves exceed their con-
trols at the highest CPA concentration that behavior is espe-
cially conspicuous in the hyperthyroid atria (Fig. 9e, f). It can
be concluded that ADA inhibition increases the efficiency of
the A1 adenosinergic direct negative inotropic function, even
in the euthyroid state. Nevertheless, consistent with our pre-
vious observation (Kemeny-Beke et al. 2007), this efficiency-
enhancing effect of ADA inhibition is stronger in hyperthy-
roidism. Based on the comparison of the present results ob-
tained using NBTI with those applying DCF, the efficiency-
enhancing effect of ADA inhibition may be speculated to be
induced by a rise in the intracellular rather than interstitial
adenosine level.
Our present results denote that ADA inhibition readjusts
the T4-induced suppression (Szentmiklosi et al. 1992; Kaasik
et al. 1994) in the capacity of the A1 receptor-mediated direct
negative inotropic function, an adenosinergic protective (en-
ergy consumption limiting) effect. The impact of this finding
stems from the fact that excess thyroid hormones place an
extra burden on the heart (Cini et al. 2009; Nabbout and
Robbins 2010) and increase the risk of ischemic heart disease,
supraventricular arrhythmias and congestive heart failure
(Franklyn and Boelaert 2012). Thus, the enhancement of en-
dogenous protective ability of the heart by means of ADA
inhibition seems to be an especially promising possibility in
hyperthyroidism.
However, an important (and until now overlooked) factor
should be also taken into account concerning the quantification
of surplus interstitial adenosine and the correction for the resulting
E/c curve transformation: the change in the signal amplification
of A1 adenosinergic system in response to ADA inhibition.
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This phenomenon could affect the assessment of cx values un-
der ADA inhibition, namely, it probably caused an overestima-
tion of cx values (Fig. 9c, d; Table 3). For explanation, the
following should be thought over. If the A1 adenosinergic ma-
chinery is more sensitive (because of ADA inhibition), a given
quantity of adenosine evokes a greater effect (Ex) and thereby
causes a larger change in the MC E/c curve. From this larger
change, a greater cx can be estimated by means of RRM (with
the use of Hill parameters of the corresponding control
MC E/c curve; see: Eq. 2). (Thus, cx values determined
under ADA inhibition are MC concentrations that are
equieffective with the surplus interstitial adenosine if it activates
an A1 adenosinergic system amplified by ADA inhibition.)
The overestimation of cx values for ADA inhibition has
two important consequences concerning our results. First, as
the efficiency enhancing effect of ADA inhibition is stronger
in the hyperthyroid atria, no conclusion is worth being drawn
from the greater cx in the presence of DCF in hyperthyroidism
(Table 3). Second, this phenomenon also affects the compar-
ison of cx values reflecting the effect of NBTI with those of
DCF. However, the former cx values are even so greater than
the latter (although overestimated) cx values (Table 3); there-
fore, the conclusion drawn previously (i.e., NBTI is superior
to DCF in increasing the interstitial adenosine level) has
remained true (moreover, it has become even truer).
At the same time, it can be stated that the corrected E/c
curves generated in the presence of DCF are even so appro-
priate. This is due to the fact that although cx values deter-
mined under ADA inhibition are overestimated, they were
used to correct E/c curves constructed under ADA inhibition.
During the correction, cx values were converted into modify-
ing effects (Ex) by means of the same Hill parameters that
were used to obtain these cx values. So, in the course of the
correction, we got correct Ex values, and these effects were
applied for further calculations. Thus, conclusions drawn from
the corrected E/c curves are all valid.
In addition, to the best of our knowledge, this study is the
first to report about the suppressing effect of T4 treatment on
the inotropic control exerted by the atrial M2 muscarinic sys-
tem in a guinea pig model. On the other hand, while thyroid
hormones remarkably decreased Emax and the potency of the
direct negative inotropic action of muscarinic agonists (MC
and carbachol) in the rat left atrium (Ishac and Pennefather
1983), we found this effect to be quite small in the guinea pig
left atrium, manifested in a moderate decrease in Emax and a
minor reduction in the Hill coefficient (Fig. 4; Table 2).
The major limitation of the present study is the pure func-
tional approach applied in it. This was necessary to unequiv-
ocally detect the nature and extent of the influence of ADA
inhibition on the contractility of the working supraventricular
myocardium. Of course, this does not substitute subsequent
molecular assays that are essential to exploit all possibilities
coming from our results.
In summary, we have found that inhibition of ADA in-
creases the signal amplification of the A1 adenosinergic sys-
tem as regards the direct negative inotropic effect in the eu-
thyroid and, a fortiori, hyperthyroid guinea pig atrium. This
outcome indicates that ADA inhibition, besides producing an
increase in the interstitial adenosine level with a consequent
stimulation of the A1 receptor, intensifies the A1 adenosinergic
direct negative inotropic function in another way (for as much
as the extra adenosine can evoke a stronger effect if using a
more efficacious signaling). Thus, our results propose a new
thyroid hormone-sensitive mechanism of action of ADA inhi-
bition that may have practical significance in improving ische-
mic tolerance of the heart. Of course, this practical impact
depends on whether this phenomenon affects other A1
receptor-mediated protective functions as well and whether it
extends to the whole heart. It is especially interesting that this
action of ADA inhibition is stronger in hyperthyroidism, a
condition that places an extra burden on the heart with a si-
multaneous reduction of some A1 receptor functions. In addi-
tion, it has been concluded that the site of the efficiency-
enhancing action of ADA inhibition is not located in the joint
part of signaling pathways of A1 and M2 receptors.
Furthermore, it has been found that ADA inhibition can pro-
duce a smaller rise in the interstitial adenosine concentration
than nucleoside transport blockade can in both eu- and hyper-
thyroid atria.
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